Do you really think if a company (penny stock or otherwise) actually had a commercially viable cancer diagnostic tool that performs according to all the MSI p/r claims, no institutional investors would be interested? As I have said many times, if they had it and it worked, partners and investors would be beating down the MSI door. Maybe that happens some day, but so far, not.
The only relevant question here is why such a vast difference between the .12 share price and the huge value of a working Flynn machine? The answer seems obvious to most.
By the way, I answered your "what market" question in my last post.
News 
Market Data 
Discover 
AI
